Phase 3 N=474 MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
Glaucoma
Primary: Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks — -2.50; -1.82; -2.78 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=106 SPECTACL: SPECTroscopic Assessment of Coronary Lipid
Angina Pectoris · Angina, Unstable · Myocardial Infarction
Primary: Spectral Similarity — 83 percent similarity
Phase 3 N=289 A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
Glaucoma · Ocular Hypertension
Primary: Change of Intraocular Pressure (IOP) From Baseline to Week 8 — -2.59; -1.62 mmHg
Phase 3 N=124 Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
Parkinson's Disease
Primary: Change in Pulse Rate (Supine, After 1 Minute) — 2.0 beats per minute
Phase 3 N=9 Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects
Community-Acquired Infections
Primary: Number of Patients by Clinical Response at Test-of-Cure (TOC) Visit. — 6; 2; 1 participants
Phase 3 N=1,873 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)
Aortic Stenosis
Primary: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) — 333; 355 Participants — p=0.591
Phase 3 N=559 A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate
Rheumatoid Arthritis
Primary: Retreated Subjects With an American College of Rheumatology 20% (ACR20) Response at Week 48 Relative to Baseline — 170; 70 Participants — p=0.0195
Phase 3 N=143 Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)
Pneumococcal Infection
Primary: Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 3 — 0.6…
Phase 3 N=515 Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
Cancer of Cervix
Primary: Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years — 55; 83; 149; 141 participants — p=0.029
Phase 3 N=1,208 MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 — -0.66; -0.82; -1.13; -1.40 Percent
Phase 3 N=349 A Study of Aripiprazole in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS) — -10.12; -6.39 units on a scale — p=<0.001
Phase 3 N=2,452 A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
Myocardial Infarction
Primary: The Composite of All-Cause Mortality or Complications of MI at 90 Days. — 86; 86; 81 participants — p=0.551
Phase 3 N=473 ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)
Herpes Zoster · Pneumococcal Infection
Primary: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination — 448.5; 371.6 gpELISA units*/mL — p=0.244
Phase 3 N=646 Effect of MK0524A on Cholesterol Levels (0524A-048)
Hypercholesterolemia · Hyperlipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks — -10.3; 4.4 Percent Change — p=<0.001
Phase 3 N=747 Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.
Fibromyalgia
Primary: Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14) — -0.73; -1.06; -1.29; -0.96 Units on a scale — p=0.2361